Treatment options for severe lupus nephritis

Archivum Immunologiae et Therapiae Experimentalis

Volumn 52, Issue 5, 2004, Pages 356-365

  Lenz, Oliver ^a   Contreras, Gabriel ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Drug therapy; Lupus erythematosus; Lupus nephritis; Systemic

Indexed keywords

AZATHIOPRINE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUDARABINE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; RAPAMYCIN; TACROLIMUS;

CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG TARGETING; GONADAL DISEASE; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MORBIDITY; MORTALITY; PATHOGENESIS; PROGNOSIS; REMISSION; REVIEW;

ADRENAL CORTEX HORMONES; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; HUMANS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 10344229949     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Alarcon G. S., McGwin G. Jr., Bastian H. M., Roseman J., Lisse J., Fessler B. J., Friedman A. W. and Reveille J. D. (2001): Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum., 45, 191-202.
2. Alarcon G. S., McGwin G. Jr., Petri M., Reveille J. D., Ramsey-Goldman R., Kimberly R. P. and PROFILE Study Group (2002): Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus, 11, 95-101.
3. Alarcon-Segovia D., Tumlin J. A., Furie R. A., McKay J. D., Cardiel M. H., Strand V., Bagin R. G., Linnik M. D., Hepburn B. and Investigator Consortium (2003): LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum., 48, 442-454.
4. Albert D. A., Hadler N. M. and Ropes M. W. (1979): Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum., 22, 945-953.
5. + T cell-B cell antibody synthesis. J. Clin. Immunol., 16, 198-207.
6. Anonymous (1995): Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet, 345, 1321-1325.
7. Appel G. B., Cohen D. J., Pirani C. L., Meltzer J. I. and Estes D. (1987): Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am. J. Med., 83, 877-885.
8. Austin H. A. III, Boumpas D. T., Vaughan E. M. and Balow J. E. (1995): High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol. Dial. Transplant., 10, 1620-1628.
9. Austin H. A. III, Klippel J. H., Balow J. E., le Riche N. G., Steinberg A. D., Plotz P. H. and Decker J. L. (1986): Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med., 314, 614-619.
10. Austin H. A. III, Muenz L. R., Joyce K. M., Antonovych T. T. and Balow J. E. (1984): Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int., 25, 689-695.
11. Austin H. A. III, Muenz L. R., Joyce K. M., Antonovych T. A., Kullick M. E., Klippel J. H., Decker J. L. and Balow J. E. (1983): Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am. J. Med., 75, 382-391.
12. Baigent C. and Landry M. (2003): Study of heart and renal protection (SHARP). Kidney Int. Suppl., S207-S210.
13. Bakris G. L., Williams M., Dworkin L., Elliott W. J., Epstein M., Toto R., Tuttle K., Douglas J., Hsueh W. and Sowers J. (2000): Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis., 36, 646-661.
14. Banda N. K., Kraus D., Vondracek A., Huynh L. H., Bendele A., Holers V. M. and Arend W. P. (2002): Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum., 46, 3065-3075.
15. Bansal V. K. and Beto J. A. (1997): Treatment of lupus nephritis: a meta-analysis of clinical trials. Am. J. Kidney Dis., 29, 193-199.
16. Barr R. G., Seliger S., Appel G. B., Zuniga R., D'Agati V., Salmon J. and Radhakrishnan J. (2003): Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol. Dial. Transplant., 18, 2039-2046.
17. Boumpas D. T., Austin H. A. III, Vaughn E. M., Klippel J. H., Steinberg A. D., Yarboro C. H. and Balow J. E. (1992): Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet, 340, 741-745.
18. Boumpas D. T., Austin H. A. III, Vaughan E. M., Yarboro C. H., Klippel J. H. and Balow J. E. (1993): Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Intern. Med., 119, 366-369.
19. Boumpas D. T., Tassiulas I. O., Fleisher T. A., Vaughan E., Piscitelli S., Kim Y., Pucino F., Balow J. E. and Austin H. A. (1999): A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin. Nephrol., 52, 67-75.
20. Brenner B. M. and Zagrobelny J. (2003): Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors. Kidney Int. Suppl., S77-S85
21. Brewster U. C., Setaro J. F. and Perazella M. A. (2003): The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am. J. Med. Sci., 326, 15-24.
22. Cade R., Spooner G., Schlein E., Pickering M., DeQuesada A., Holcomb A., Juncos L., Richard G., Shires D., Levin D., Hackett R., Free J., Hunt R. and Fregly M. (1973): Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron, 10, 37-56.
23. Calvani N., Satoh M., Croker B. P., Reeves W. H. and Richards H. B. (2003): Nephritogenic autoantibodies but absence of nephritis in II-12p35-deficient mice with pristane-induced lupus. Kidney Int., 64, 897-905.
24. Cameron J. S. (1999): Lupus nephritis. J. Am. Soc. Nephrol., 10, 413-424.
25. Carvalho-Pinto C. E., Garcia M. I., Mellado M., Rodriguez-Frade J. M., Martin-Caballero J., Flores J., Martinez A. and Balomenos D. (2002): Autocrine production of IFN-γ by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. J. Immunol., 169, 1058-1067.
26. Cathcart E. S., Idelson B. A., Scheinberg M. A. and Couser W. G. (1976): Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis. Lancet, 1, 163-166.
27. Cattran D. C. (2003): Cyclosporine in the treatment of idiopathic focal segmental glomerulosclerosis. Semin. Nephrol., 23, 234-241.
28. Cattran D. C. (2003): Mycophenolate mofetil and cyclosporine therapy in membranous nephropathy. Semin. Nephrol., 23, 272-277.
29. Chan O. T., Madaio M. P. and Shlomchik M. J. (1999): The central and multiple roles of B cells in lupus pathogenesis. Immunol. Rev., 169, 107-121.
30. Chan T. M., Li F. K., Tang C. S., Wong R. W., Fang G. X., Ji Y. L., Lau C. S., Wong A. K., Tong M. K., Chan K. W. and Lai K. N. (2000): Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med., 343, 1156-1162.
31. Chan T. M., Li F. K., Wong R. W., Wong K. L., Chan K. W. and Cheng I. K. (1995): Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron, 71, 321-327.
32. Chan T. M., Wong W. S., Lau C. S. et al. (2001): Prolonged follow-up of patients with diffuse proliferative lupus nephritis (DPLN) treated with prednisolone and mycophenolate mofetil (MMF) [Abstract]. J. Am. Soc. Nephrol., 12, 195A.
33. Charles P. J., Smeenk R. J., De Jong J., Feldmann M. and Maini R. N. (2000): Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum., 43, 2383-2390.
34. Cheigh J. S. and Stenzel K. H. (1993): End-stage renal disease in systemic lupus erythematosus. Am. J. Kidney Dis., 21, 2-8.
35. Choy E. H., Panayi G. S., Emery P., Madden S., Breedveld F. C., Kraan M. C., Kalden J. R., Rascu A., Brown J. C., Rapson N. and Johnston J. M. (2002): Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology, 41, 1142-1148.
36. Clark W. F. and Moist L. M. (1998): Management of chronic renal insufficiency in lupus nephritis: role of proteinuria, hypertension and dyslipidemia in the progression of renal disease. Lupus, 7, 649-653.
37. Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P. and Roth D. (2004): Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med., 350, 971-980.
38. Corna D., Morigi M., Facchinetti D., Bertani T., Zoja C. and Remuzzi G. (1997): Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int., 51, 1583-1589.
39. Datta S. K., Kaliyaperumal A. and Desai-Mehta A. (1997): T cells of lupus and molecular targets for immunotherapy. J. Clin. Immunol., 17, 11-20.
40. Davis J. C. Jr., Austin H. III, Boumpas D., Fleisher T. A., Yarboro C., Larson A., Balow J., Klippel J. H. and Scott D. (1998): A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum., 41, 335-343.
41. Davis J. C. Jr., Totoritis M. C., Rosenberg J., Sklenar T. A. and Wofsy D. (2001): Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol., 28, 95-101.
42. de Deus R. B., Ferreira A. C., Kirsztajn G. M. and Heilberg I. P. (2003): Osteopenia in patients with glomerular diseases requiring long-term corticosteroid therapy. Nephron Clin. Practice, 94, c69-c74.
43. De Vries B., Matthijsen R. A., Wolfs T. G., Van Bijnen A. A., Heeringa P. and Buurman W. A. (2003): Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation, 75, 375-382.
44. Deegens J. K., Artz M. A., Hoitsma A. J. and Wetzels J. F. (2003): Outcome of renal transplantation in patients with systemic lupus erythematosus. Transpl. Int., 16, 411-418.
45. Dinant H. J., Decker J. L., Klippel J. H., Balow J. E., Plotz P. H. and Steinberg A. D. (1982): Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann. Intern. Med., 96, 728-736.
46. Djamali A., Premasathian N. and Pirsch J. D. (2003): Outcomes in kidney transplantation. Semin. Nephrol., 23, 306-316.
47. Dooley M. A., Cosio F. G., Nachman P. H., Falkenhain M. E., Hogan S. L., Falk R. J. and Hebert L. A. (1999): Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J. Am. Soc. Nephrol., 10, 833-839.
48. Dosa S., Cairns S. A., Lawler W., Mallick N. P. and Slotki I. N. (1978): The treatment of lupus nephritis by methyl prednisolone pulse therapy. Postgrad. Med. J., 54, 628-632.
49. Dostal C., Tesar V., Rychlik I., Zabka J., Vencovsky J., Bartunkova J., Stejskalova A. and Tegzova D. (1998): Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus, 7, 29-36.
50. Duddridge M. and Powell R. J. (1997): Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann. Rheum. Dis., 56, 690-692.
51. Early G. S., Zhao W. and Burns C. M. (1996): Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black X New Zealand white mice. Response correlates with the absence of an anti-antibody response. J. Immunol., 157, 3159-3164.
52. Eisenberg R. (2003): SLE - Rituximab in lupus. Arthritis Res. Ther., 5, 157-159.
53. Entani C., Izumino K., Iida H., Fujita M., Asaka M., Takata M. and Sasayama S. (1993): Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron, 64, 471-475.
54. Espinoza L. R. (1996): Antiphospholipid antibody syndrome: treatment. Lupus, 5, 456-457.
55. Feldmann M. and Maini R. N. (2001): Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol., 19, 163-196.
56. Felson D. T. and Anderson J. (1984): Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N. Engl. J. Med., 311, 1528-1533.
57. Flanc R. T., Roberts M. A., Strippoli G. F. M., Chadban S. J., Kerr P. G. and Atkins R. C. (2004): Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled clinical trials. Am. J. Kidney Dis., 43, 197-208.
58. Fra G. P., Avanzi G. C. and Bartoli E. (2003): Remission of refractory lupus nephritis with a protocol including rituximab. Lupus, 12, 783-787.
59. Fried L. F., Orchard T. J. and Kasiske B. L. (2001): Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int., 59, 260-269.
60. Furie R. A., Cash J. M., Cronin M. E., Katz R. S., Weisman M. H., Aranow C., Liebling M. R., Hudson N. P., Berner C. M., Coutts S. and de Haan H. A. (2001): Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol., 28, 257-265.
61. Ginzler E. M., Aranow C., Buyon J., Dooley M. A., Merrill J. T., Petri M., Appel G., Gilkeson G., Wallace D. and Weisman M. (2003): A multicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN): preliminary results [Abstract]. Arthritis Rheum., 48, S647.
62. Ginzler E., Diamond H., Guttadauria M. and Kaplan D. (1976): Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis Rheum., 19, 693-699.
63. Glicklich D. and Acharya A. (1998): Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am. J. Kidney Dis., 32, 318-322.
64. Goral S., Ynares C., Shappell S. B., Snyder S., Feurer I. D., Kazancioglu R., Fogo A. B. and Helderman J. H. (2003): Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. Transplantation, 75, 651-656.
65. Gourley M. F., Austin H. A. III, Scott D., Yarboro C. H., Vaughan E. M., Muir J., Boumpas D. T., Klippel J. H., Balow J. E. and Steinberg A. D. (1996): Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med., 125, 549-557.
66. Hahn B. H., Kantor O. S. and Osterland C. K. (1975): Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann. Intern. Med., 83, 597-605.
67. Halloran P., Mathew T., Tomlanovich S., Groth C., Hooftman L. and Barker C. (1997): Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation, 63, 39-47.
68. Hiepe F., Volk H. D., Apostoloff E., von Baehr R. and Emmrich F. (1991): Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody. Lancet, 338, 1529-1530.
69. Hochberg M. C. (1985): The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. Arthritis Rheum., 28, 80-86.
70. Hochberg M. C. (1997): Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum., 40, 1725.
71. Houssiau F. A. and Jadoul M. (2002): Cytotoxic therapy of lupus nephritis: recent developments. Nephrol. Dial. Transplant., 17, 955-957.
72. Houssiau F. A., Vasconcelos C., D'Cruz D., Sebastiani G. D., Garrido Ed E. R., Danieli M. G., Abramovicz D., Blockmans D., Mathieu A., Direskeneli H., Galeazzi M., Gul A., Levy Y., Petera P., Popovic R., Petrovic R., Sinico R. A., Cattaneo R., Font J., Depresseux G., Cosyns J. P. and Cervera R. (2002): Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum., 46, 2121-2131.
73. Hussein M. M., Mooij J. M. and Roujouleh H. (1993): Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin. Nephrol., 40, 160-163.
74. Illei G. G., Austin H. A., Crane M., Collins L., Gourley M. F., Yarboro C. H., Vaughan E. M., Kuroiwa T., Danning C. L., Steinberg A. D., Klippel J. H., Balow J. E. and Boumpas D. T. (2001): Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med., 135, 248-257.
75. Illei G. G., Takada K., Parkin D., Austin H. A., Crane M., Yarboro C. H., Vaughan E. M., Kuroiwa T., Danning C. L., Pando J., Steinberg A. D., Gourley M. F., Klippel J. H., Balow J. E. and Boumpas D. T. (2002): Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum., 46, 995-1002.
76. Isaacs J. D. (2001): From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies. Rheumatology, 40, 724-738.
77. Jones B. M., Liu T. and Wong R. W. (1999): Reduced in vitro production of interferon-γ, interleukin-4 and interleukin-12 and increased production of interleukin-6, interleukin-10 and tumour necrosis factor-α in systemic lupus erythematosus. Weak correlations of cytokine production with disease activity. Autoimmunity, 31, 117-124.
78. Jonsson C. A., Svensson L. and Carlsten H. (1999): Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin. Exp. Immunol., 116, 534-541.
79. Joseph R. E., Radhakrishnan J. and Appel G. B. (2001): Antiphospholipid antibody syndrome and renal disease. Curr. Opin. Nephrol. Hypertens, 10, 175-181.
80. Joy M. S., Neyhart C. D. and Dooley M. A. (2000): A multidisciplinary renal clinic for corticosteroid-induced bone disease. Pharmacotherapy, 20, 206-216.
81. Kaplan M. (2002): Eculizumab (Alexion). Curr. Opin. Investig. Drugs, 3, 1017-1023.
82. Kart K. H., Yucel A. E., Kunefeci G., Ozdemir F. N. and Duran H. (2001): Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus, 10, 818-820.
83. Kewalramani R. and Singh A. K. (2002): Immunopathogenesis of lupus and lupus nephritis: recent insights. Curr. Opin. Nephrol. Hypertens, 11, 273-277.
84. Khamashta M. A., Cuadrado M. J., Mujic F., Taub N. A., Hunt B. J. and Hughes G. R. (1995): The management of thrombosis in the antiphospholipid- antibody syndrome. N. Engl. J. Med., 332, 993-997.
85. Kiberd B. A. (1993): Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J. Am. Soc. Nephrol., 4, 58-61.
86. Kikawada E., Lenda D. M. and Kelley V. R. (2003): IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-γ expression, and diminishes systemic pathology. J. Immunol., 170, 3915-3925.
87. Korbet S. M., Lewis E. J., Schwartz M. M., Reichlin M., Evans J. and Rohde R. D. (2000): Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am. J. Kidney Dis., 35, 904-914.
88. Kusunoki Y., Akutsu Y., Itami N., Tochimaru H., Nagata Y., Takekoshi Y., Sagawa A., Kataoka Y. and Nagasawa S. (1991): Urinary excretion of terminal complement complexes in glomerular disease. Nephron, 59, 27-32.
89. Lawrence R. C., Helmick C. G., Arnett F. C., Deyo R. A., Felson D. T., Giannini E. H., Heyse S. P., Hirsch R., Hochberg M. C., Hunder G. G., Liang M. H., Pillemer S. R., Steen V. D. and Wolfe F. (1998): Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum., 41, 778-799.
90. Levey A. S., Lan S. P., Corwin H. L., Kasinath B. S., Lachin J., Neilson E. G., Hunsicker L. G. and Lewis E. J. (1992): Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann. Intern. Med., 116, 114-123.
91. Lewis E. J., Hunsicker L. G., Lan S. P., Rohde R. D. and Lachin J. M. (1992): A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N. Engl. J. Med., 326, 1373-1379.
92. Liu T. F. and Jones B. M. (1998): Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine, 10, 140-147.
93. Llorente L., Richaud-Patin Y., Garcia-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M. H., Alcocer-Varela J., Grangeot-Keros L., Alarcon-Segovia D., Wijdenes J., Galanaud P. and Emilie D. (2000): Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum., 43, 1790-1800.
94. Lucas J. A., Ahmed S. A., Casey M. L. and MacDonald P. C. (1985): Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone. J. Clin. Invest., 75, 2091-2093.
95. McCarty D. J., Manzi S., Medsger T. A. Jr., Ramsey-Goldman R., LaPorte R. E. and Kwoh C. K. (1995): Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum., 38, 1260-1270.
96. McCluske R. T. (1975): Lupus nephritis. In Sommer S. C., East Norwalk C. T. (eds.): Kidney Pathology Decennial 1966-1975 Appleton-Century-Crofts, pp 435-450.
97. Meyrier A. (2003): Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol. Dial. Transplant., 18 (suppl.) 86.
98. Miyake K., Nakashima H., Akahoshi M., Inoue Y., Nagano S., Tanaka Y., Masutani K., Hirakata H., Gondo H., Otsuka T. and Harada M. (2002): Genetically determined interferon-γ production influences the histological phenotype of lupus nephritis. Rheumatology, 41, 518-524.
99. Mok C. C., Ho C. T., Chan K. W., Lau C. S. and Wong R. W. (2002): Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum., 46, 1003-1013.
100. Mok C. C., Ho C. T., Siu Y. P., Chan K. W., Kwan T. H., Lau C. S., Wong R. W. and Au T. C. (2001): Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am. J. Kidney Dis., 38, 256-264.
101. Mok C. C., Lau C. S. and Wong R. W. (1998): Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum., 41, 831-837.
102. Moreland L. W., Alten R., Van den Bosch F., Appelboom T., Leon M., Emery P., Cohen S., Luggen M., Shergy W., Nuamah I. and Becker J. C. (2002): Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-41g and LEA29Y eighty-five days after the first infusion. Arthritis Rheum., 46, 1470-1479.
103. Morel-Maroger L., Mery J. P., Droz D., Godin M., Verroust P., Kourilsky O. and Richet G. (1976): The course of lupus nephritis: contribution of serial renal biopsies. Adv. Nephrol. Necker Hosp., 6, 79-118.
104. Moroni G., Quaglini S., Maccario M., Banfi G. and Ponticelli C. (1996): "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int., 50, 2047-2053.
105. Moroni G., Tantardini F. and Ponticelli C. (2003): Renal replacement therapy in lupus nephritis. J. Nephrol., 16, 787-791.
106. National Institute of Diabetes and Digestive and Kidney Diseases (2004): Sirolimus therapy in idiopathic and lupus membranous. Nephropathy.
107. Nossent H. C. and Koldingsnes W. (2000): Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology, 39, 969-974.
108. Orth S. R. (2004): Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J. Am. Soc. Nephrol., 15, S63.
109. Pasquali S., Banfi G., Zucchelli A., Moroni G., Ponticelli C. and Zucchelli P. (1993): Lupus membranous nephropathy: long-term outcome. Clin. Nephrol., 39, 175-182.
110. Perrotta S., Locatelli F., La Manna A., Cennamo L., De Stefano P. and Nobili B. (2002): Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytie anaemia in a patient with systemic lupus erythematosus. Br. J. Haematol., 116, 465-467.
111. Pollak V. E., Pirani C. L. and Schwartz F. D. (1964): The natural history of the renal manifestations of systemic lupus erythematosus. J. Lab. Clin. Med., 63, 537-550.
112. Ponticelli C., Zucchelli P., Banfi G., Cagnoli L., Scalia P., Pasquali S. and Imbasciati E. (1982): Treatment of diffuse proliferative tupus nephritis by intravenous high-dose methylprednisolone. Q. J. Med., 51, 16-24.
113. Radhakrishnan J., Kunis C. L., D'Agati V. and Appel G. B. (1994): Cyclosporine treatment of lupus membranous nephropathy. Clin. Nephrol., 42, 147-154.
114. Radis C. D., Kahl L. E., Baker G. L., Wasko M. C., Cash J. M., Gallatin A., Stolzer B. L., Agarwal A. K., Medsger T. A. Jr. and Kwoh C. K. (1995): Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum., 38, 1120-1127.
115. Remuzzi G., Ruggenenti P. and Perico N. (2002): Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann. Intern. Med., 136, 604-615.
116. Ruggenenti P., Brenner B. M. and Remuzzi G. (2001): Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron, 88, 254-259.
117. Schiffer L. E., Hussain N., Wang X., Huang W., Sinha J., Ramanujam M. and Davidson A. (2002): Lowering anti-dsDNA antibodies - what's new? Lupus, 11, 885-894.
118. Schulze M., Donadio J. V. Jr., Pruchno C. J., Baker P. J., Johnson R. J., Stahl R.A., Watkins S., Martin D. C., Wurzner R. and Gotze O. (1991): Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int., 40, 533-538.
119. Shernan S. K., Fitch J. C., Nussmeier N. A., Chen J. C., Rollins S. A., Mojcik C. F., Malloy K. J., Todaro T. G., Filloon T., Boyce S. W., Gangahar D. M., Goldberg M., Saidman L. J., Mangano D. T. and Pexelizumab S. I. (2004): Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann. Thorac. Surg., 77, 942-949.
120. Siegel M., Holley H. L. and Lee S. L. (1970): Epidemiologic studies on systemic lupus erythematosus. Comparative data for New York City and Jefferson County, Alabama, 1956-1965. Arthritis Rheum., 13, 802-811.
121. Steinberg A. D. and Steinberg S. C. (1991): Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum., 34, 945-950.
122. Strand V., Aranow C., Cardiel M. H., Alarcon-Segovia D., Furie R., Sherrer Y., Tumlin J., Wallace D. J., Crawford B. and Investigator Consortium (2003): Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus, 12, 677-686.
123. Tam L. S., Li E. K., Leung C. B., Wong K. C., Lai F. M., Wang A., Szeto C. C. and Lui S. F. (1998): Long-term treatment of lupus nephritis with cyclosporin A. QJM, 91, 573-580.
124. Taylor P. C. (2003): Antibody therapy for rheumatoid arthritis. Curr. Opin. Pharmacol., 3, 323-328.
125. Thurman J. M. and Schrier R. W. (2003): Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am. J. Med., 114, 588-598.
126. Uramoto K. M., Michet C. J. Jr., Thumboo J., Sunku J., O'Fallon W. M. and Gabriel S. E. (1999): Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum., 42, 46-50.
127. van den Wall Bake A. W., Berden J. H., Derksen R. H., Glas-Vos J. W. and Hagen E. C. (1994): Therapy of proliferative lupus glomerulonephritis: a prospective trial in The Netherlands. Neth. J. Med., 45, 280-284.
128. van Vollenhoven R. F., Engleman E. G. and McGuire J. L. (1995): Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum., 38, 1826-1831.
129. van Vollenhoven R. F., Park J. L., Genovese M. C., West J. P. and McGuire J. L. (1999): A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus, 8, 181-187.
130. Wallace D. J., Goldfinger D., Pepkowitz S. H., Fichman M., Metzger A. L., Schroeder J. O. and Euler H. H. (1998): Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J. Clin. Apheresis, 13, 163-166.
131. Wang C. L., Wang F. and Bosco J. J. (1995): Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus, 4, 11-14.
132. Weening J. J., D'Agati V. D., Schwartz M. M., Seshan S. V., Alpers C. E., Appel G. B., Balow J. E., Bruijn J. A., Cook T., Ferrario F., Fogo A. B., Ginzler E. M., Hebert L., Hill G., Hill P., Jennette J. C., Kong N. C., Lesavre P., Lockshin M., Looi L. M., Makino H., Moura L. A., Nagata M. and International Society of Nephrology Working Group on the Classification of Lupus Nephritis, Renal Pathology Society Working Group on the Classification of Lupus Nephritis (2004): The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int., 65, 521-530.
133. Wei N., Klippel J. H., Huston D. P., Hall R. P., Lawley T. J., Balow J. E., Steinberg A. D. and Decker J. L. (1983): Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet, 1, 17-22.
134. Wolfe R. A., Ashby V. B., Milford E. L., Ojo A. O., Ettenger R. E., Agodoa L. Y., Held P. J. and Port F. K. (1999): Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med., 341, 1725-1730.
135. Yoshio T., Masuyama J. I., Kohda N., Hirata D., Sato H., Iwamoto M., Mimori A., Takeda A., Minota S. and Kano S. (1997): Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J. Rheumatol., 24, 489-495.